Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 20 of 58, showing 10 Applications out of 576 total, starting on record 191, ending on 200

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

191.

ECCT/23/02/03   INTREPiD
    Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy with High-Sensitivity Diagnostics (INTREPiD).   
Principal Investigator(s)
1. Steve M Taylor
2. Jeremiah K Laktabai
Site(s) in Kenya
Bungoma County
 
23-07-2023 View

192.

ECCT/23/03/07   PLATINUM STUDY
    (PLATINUM): A multi-part, multi-center PLATform study to assess the efficacy, safety, tolerability and pharmacokinetics of anti-malarial agents administered as monotherapy and/or combination therapy IN patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Godfrey (Site 5001) Allan Otieno
2. Bernhard Ragama Ogutu
3. John (Site 5002) Orimbo
Site(s) in Kenya
1. KEMRI Kondele Children Hospital (Kisumu county)
2. AHERO CLINICAL TRIALS UNIT (Kisumu county)
 
21-07-2023 View

193.

ECCT/23/04/05   BiMVaC01
    A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults.   
Principal Investigator(s)
1. NDUNGU FRANCIS
2. Said Jongo
Site(s) in Kenya
KEMRI-CGMRC Kilifi
 
06-07-2023 View

194.

ECCT/23/02/06   BOHEMIA Safety and Efficacy
    A Phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in Kwale, Kenya.         
Principal Investigator(s)
1. Marta Ferreira Maia
2. Joseph Mwangangi
Site(s) in Kenya
Kwale county, subcounties Lungalunga and Msambweni
 
25-06-2023 View

195.

ECCT/23/01/03   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Githanga Githanga Nyokabi
Site(s) in Kenya
1. Gertrude\'s Children Hospital (Nairobi City county)
2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county)
4. Kombewa CRC (Kisumu county)
 
19-06-2023 View

196.

ECCT/23/02/01   Hibiscus Kid\'s Study
    A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Videlis Nduba
2. Walter Otieno
3. Isaac Tsikhutsu
Site(s) in Kenya
1. AHERO CLINICAL TRIALS UNIT (Kisumu county)
2. KEMRI-Walter Reed-Kericho (Kericho county)
3. KEMRI: Siaya Clinical Research Annexe (Kisumu county)
4. Kombewa Clinical Research Centre (Kisumu county)
 
14-06-2023 View

197.

ECCT/23/04/03   ACTIV-2d/A5407
    A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19   
Principal Investigator(s)
1. Prof Abraham Mosigisi Siika
Site(s) in Kenya
1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
2. Victoria Biomedical Research Institute, (Kisumu county)
3. Kenyatta National Hospital (Nairobi City county)
4. KEMRI CCR – BUTERE SITE (Kakamega county)
5. Kenya Medical Research Institute/Walter Reed Project (Kericho county)
6. KEMRI – AHERO Clinical Trials Units (Kisumu county)
 
14-06-2023 View

198.

ECCT/23/01/06   FENHANCE
    A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS         CSF BIOMARKER SUBSTUDY ASSOCIATED WITH A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY (GN41851) TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS        
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
13-06-2023 View

199.

ECCT/23/02/05   Pharmacy PrEP cRCT
    Pharmacy delivery to expand the reach of PrEP in Kenya: cluster-randomized control trial   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Kenneth Ngure
Site(s) in Kenya
1. Kenya Medical Research Institute, Center for Microbiology Research, Research Care and Training Programme (KEMRI-CMR-RCTP) research center (Kisumu county)
2. Kenya Medical Research Institute, Center for Clinical Research, Partners in Health and Research Development (KEMRI-CCR-PHRD) research center (Kiambu county)
 
07-06-2023 View

200.

ECCT/23/01/04   ACTIV-2d/A5407
    A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19   
Principal Investigator(s)
1. Lucas Tina Otieno
Site(s) in Kenya
1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
2. Victoria Biomedical Research Institute, (Kisumu county)
3. Kenya Medical Research Institute/Walter Reed Project (Kericho county)
4. Kenyatta National Hospital (Nairobi City county)
5. Ahero Clinical Trials Unit, (Kisumu county)
6. KEMRI CCR – BUTERE SITE (Kakamega county)
 
01-06-2023 View